Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
As the global economy mends, the 2021 growth of Parkinson Disease Drug will have significant change from previous year. According to our (LP Information) latest study, the global Parkinson Disease Drug market size is USD million in 2022 from USD 5372.5 million in 2021, with a change of % between 2021 and 2022. The global Parkinson Disease Drug market size will reach USD 8289.7 million in 2028, growing at a CAGR of 6.4% over the analysis period.
The United States Parkinson Disease Drug market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Parkinson Disease Drug market, reaching US$ million by the year 2028. As for the Europe Parkinson Disease Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Parkinson Disease Drug players cover Merck, Akorn, GSK, and Novartis, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Parkinson Disease Drug market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Sinemet-CR
Trastal
Madopar
COMT Inhibitor
Other
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Under 40 Years Old
40-65 Years Old
Above 65 Years Old
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Merck
Akorn
GSK
Novartis
Boehringer Ingelheim
Teva Pharmaceutical
Abbvie
Kyowa Hakko Kirin Pharma
Astellas Pharma
Desitin Arzneimittel
Endo Pharmaceuticals
F.Hoffmann-La Roche
H.Lundbeck
Valeant
Apokyn
Orion
Stada Arzneimittel
US WorldMeds
Bausch Health
The United States Parkinson Disease Drug market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Parkinson Disease Drug market, reaching US$ million by the year 2028. As for the Europe Parkinson Disease Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Parkinson Disease Drug players cover Merck, Akorn, GSK, and Novartis, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Parkinson Disease Drug market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Sinemet-CR
Trastal
Madopar
COMT Inhibitor
Other
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Under 40 Years Old
40-65 Years Old
Above 65 Years Old
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Merck
Akorn
GSK
Novartis
Boehringer Ingelheim
Teva Pharmaceutical
Abbvie
Kyowa Hakko Kirin Pharma
Astellas Pharma
Desitin Arzneimittel
Endo Pharmaceuticals
F.Hoffmann-La Roche
H.Lundbeck
Valeant
Apokyn
Orion
Stada Arzneimittel
US WorldMeds
Bausch Health
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
